ClinicalTrials.gov confirms that this Phase 3 study is registered and currently listed as Active Not Recruiting. This establishes the study's existence and registry-reported design/status, not a treatment benefit.
In the randomized, double-blind, phase 3 LEAP-012 trial, adding lenvatinib and pembrolizumab to TACE significantly extended progression-free survival compared with TACE alone (14.6 months versus 10.0 months) in patients with…
In the randomized, double-blind, phase 3 LEAP-012 trial, adding lenvatinib and pembrolizumab to TACE significantly extended progression-free survival compared with TACE alone (14.6 months versus 10.0 months) in patients with…
✓ Primary source cited
Last reviewed
Clinical Trials
Important: Eligibility and enrollment are not guaranteed, and listing here is not a treatment recommendation. Talk to your care team.
Adults with unresectable, non-metastatic, intermediate-stage hepatocellular carcinoma (liver cancer) without extrahepatic spread or vascular invasion, randomized to transarterial chemoembolization (TACE) plus lenvatinib plus pembrolizumab, or TACE plus dual placebo, at 137 sites across 33 countries.
Last reviewed
2026-08-13
Regulatory status by jurisdiction
Unspecified jurisdiction
Status
Investigational
Last verified
2026-08-13
This record has no structured cancer-type scope on file yet — editorial review recommended before treating it as applicable to a specific cancer type.
LEAP-012: transarterial chemoembolisation combined with lenvatinib plus pembrolizumab versus dual placebo for unresectable, non-metastatic hepatocellular carcinoma (The Lancet). DOI 10.1016/S0140-6736(24)02575-3.
CancerDiscoveries summarizes verified records in its database. Absence of a listing here does not establish that a treatment lacks regulatory authorization or access.